Pharmaceuticals

Covidien (COV), a leading global health care products company with a focus on mechanical ventilation and respiratory care devices, recently announced the integration of its new Infinity MCable and Nellcor OxiMax knowhow with the Drager Infinity Acute Care System in European nations. The Infinity...

Oppenheimer is raising its target on shares of Ardea Biosciences, Inc. (NASDAQ: RDEA) to $32 on Positive '594 Data. “We are raising our PT to $32 from $27 on the positive Phase IIb data,” Oppenheimer writes. “Specifically, we have raised our estimate of probability of success of '594 in gout from...

RBC Capital increases its price target on the following companies: Valeant Pharmaceuticals (NYSE: VRX) from $34 to $41. TJX (NYSE: TJX) from $50 to $52. Ross Stores (NASDAQ: ROST) from $62 to $64. Quanta Services (NYSE: PWR) from $22 to $25. Pioneer Natural Resources (NYSE: PXD) from $89 to $98....

Amarin Corporation plc (Nasdaq: AMRN) today announced that, in connection with its previously announced underwritten public offering of American Depositary Shares, the underwriters of the offering have exercised in full their option to purchase up to an aggregate of 1,800,000 additional ADSs to...

Shares of Valeant Pharmaceuticals (NYSE: VRX) ended the day up 19% following its 2011 guidance introduction that brought much in the way of improved visibility around the story. Both revenue and EPS guidance ranges were above Street estimates while synergy and tax forecasts were raised, which...

Covidien (COV), a leading global health care products company with a focus on mechanical ventilation and respiratory care devices, recently announced the integration of its new Infinity MCable and Nellcor OxiMax knowhow with the Drager Infinity Acute Care System in European nations. The Infinity...

Goldman Sachs is raising its 12-month price target on Valeant Pharmaceutical (NYSE: VRX) to $34 from $30 “on higher estimates and a one-quarter roll forward.”

Piper Jaffray is raising its target on Valeant Pharmaceutical (NYSE: VRX) to $41, up from $35.

Jefferies is raising its PT on Ardea Biosciences, Inc. (NASDAQ: RDEA) to $32 from $30.

Below are the top small-cap drug delivery stocks on the NYSE and the NASDAQ in terms of cash. Alkermes Inc (NASDAQ: ALKS) had $230.48 million in total cash and no debt for the latest quarter. PetMed Express Inc (NASDAQ: PETS) had $70.60 million in total cash and no debt for the latest quarter. KV...

We are upgrading Enzon Pharmaceuticals Inc. (ENZN) to Neutral from Underperform, with a price target of $13.00, based on its promising future prospects. The debt burden at Enzon has reduced significantly following the sale of its specialty pharmaceutical business. In January 2010, Enzon sold...

We are upgrading Enzon Pharmaceuticals Inc. (ENZN) to Neutral from Underperform, with a price target of $13.00, based on its promising future prospects. The debt burden at Enzon has reduced significantly following the sale of its specialty pharmaceutical business. In January 2010, Enzon sold...

A number of stocks were lighting up screens across Wall Street on Thursday. Names that were bleeding red included Gap (NYSE: GPS) and Target (NYSE: TGT), both of which reported weaker than expected same store sales numbers. GPS shares fell 6.88% to $20.70. TGT lost 6.80% to $54.93. Both stocks...

Roche Holdings Ltd. (RHHBY) recently announced that the US Food and Drug Administration (FDA) approved Actemra (tocilizumab) to be used for slowing structural joint damage, improving physical function, and achieving major clinical response in adult patients with moderately to severely active...